BPC-157 Mechanism of Action: Pathways and Research

Research use only. BPC-157 is supplied as a research-grade reference compound for laboratory research use only. It is not for human or veterinary use. This page describes published animal-model and in vitro literature and does not describe use in people.

BPC-157 is a synthetic 15-residue peptide whose sequence corresponds to a partial sequence identified in the protein BPC, isolated from human gastric juice. It is described in the literature as a stable gastric pentadecapeptide, and the published research examines its behavior in animal-model and in vitro systems across angiogenic and cytoprotective signaling pathways.

This page covers where the molecule comes from, the research program that produced most of the literature, and the signaling pathways reported in that work. Sequence, molecular weight, synthesis and analytical characterization are covered separately in BPC-157 structure, sequence and synthesis.

Where Does BPC-157 Come From?

BPC-157 is a synthetic peptide whose sequence corresponds to residues found within BPC, a protein isolated from human gastric juice. BPC stands for body protection compound, the name given to the parent protein by the group that characterized it. The 15-residue fragment is manufactured by chemical synthesis rather than extracted from a biological source, so the supplied reference material is a synthetic peptide with a defined sequence, not a purified natural product. Molecular identity data for that sequence is set out in the BPC-157 chemical reference data.

Two points follow from this and they are the ones the literature returns to. First, the descriptor “stable gastric pentadecapeptide” that appears throughout the published work refers to reported stability in gastric juice, which is the property that distinguished the fragment in the original characterization. Second, because the material is synthetic, its identity and purity are established by analytical chemistry on the manufactured lot rather than inherited from a biological origin.

Term used in the literature	What it refers to
BPC	The parent protein described as isolated from human gastric juice.
Body protection compound	The expanded form of the BPC abbreviation used by the originating research group.
BPC 1-70	The parent protein sequence as numbered in the source literature.
BPC-157	The synthetic 15-residue peptide corresponding to a partial sequence of that protein. This is the reference compound.
Stable gastric pentadecapeptide	The descriptor used across the published literature, referring to reported stability in gastric juice and to the 15-residue length.

Amino Acid Composition

BPC-157 is a pentadecapeptide, meaning it is 15 amino acid residues long. The full sequence, molecular weight and the analytical methods used to confirm them are set out in the structure and synthesis article, which is the page to read for composition questions.

The Research Program Behind the Literature

Most published BPC-157 work traces to a single research program led by Predrag Sikiric and colleagues, beginning with characterization of the parent compound in the early 1990s and continuing through pathway-level studies. Naming the lineage matters when reading the evidence base, because breadth of publication is not the same as breadth of independent replication.

Period	What the literature added	Representative reference
Early 1990s	Characterization of the gastroprotective effect of the parent body protection compound.	Acta Physiol Hung, 1992; PMID 1345210
2011	Tendon-model work connecting the peptide to fibroblast behavior.	J Appl Physiol, 2011; PMID 21030672
2017	Association of pro-angiogenic effects with VEGFR2 activation.	J Mol Med, 2017; PMID 27847966
2018	Comparison with standard angiogenic growth factors in gastrointestinal models.	Curr Pharm Des, 2018; PMID 29998800
2020	Vasomotor tone and Src-Caveolin-1-eNOS pathway activation.	Sci Rep, 2020; PMID 33051481
2021 onward	Consolidating reviews across wound-healing and regenerative models.	Front Pharmacol, 2021; PMID 34267654

Recent narrative reviews have also begun to weigh the limits of the evidence rather than only summarizing it, which is the more useful framing for a researcher deciding what a given result supports (Curr Rev Musculoskelet Med, 2025; PMID 40789979).

Research Focus: Signaling Pathways in the Published Literature

The mechanistic literature describes several signaling pathways. The table states each alongside the model system it was observed in, because results from cell culture, rodent models and cell-free systems are not interchangeable and the distinction is frequently lost when these findings are summarized elsewhere. Tendon-model findings are set against TB-500 in BPC-157 compared with TB-500 in tendon models.

Pathway	Model system in the cited work	What the literature describes	Reference
VEGFR2	Cell and animal models	Association of pro-angiogenic effects with VEGFR2 activation and downstream signaling.	J Mol Med, 2017; PMID 27847966
Src-Caveolin-1-eNOS	Rodent vascular preparations	Modulation of vasomotor tone through this pathway, linking the peptide to nitric oxide signaling.	Sci Rep, 2020; PMID 33051481
Nitric oxide system	Multiple animal models	Interaction with nitric oxide signaling described across the angiogenesis literature.	Pharmaceuticals, 2025; PMID 41155565
Growth factor signaling	Gastrointestinal animal models	Effects compared against standard angiogenic growth factors in the same models.	Curr Pharm Des, 2018; PMID 29998800
Fibroblast and tendon cell behavior	Rodent tendon models and isolated cells	Effects on tendon fibroblast outgrowth and related cellular readouts.	J Appl Physiol, 2011; PMID 21030672
Ischemia-reperfusion models	Rodent brain models	Effects reported in hippocampal ischemia and reperfusion injury models.	Brain Behav, 2020; PMID 32558293

Read across the table, the recurring theme in this literature is vascular and angiogenic signaling rather than a single receptor interaction. No high-affinity receptor for the peptide has been established in the published work, which is a meaningful gap when comparing it against compounds with defined receptor pharmacology, a subject covered in receptor pharmacology and peptide binding.

Pharmacokinetics in Published Models

Published animal-model studies define their own experimental parameters, and those parameters vary across models, species and endpoints. Study design decisions of this kind are governed by the protocol of the individual study and by institutional animal care and use committee review, and they are documented in the methodology of the paper rather than generalized across the literature.

For any given model, the primary publication is the correct source. Extrapolating experimental parameters between models or across species is not supported by this literature.

Chemical Identity and Verification

For a synthetic reference peptide, identity and purity are established analytically on the manufactured lot. A certificate of analysis should confirm the molecule by mass spectrometry, report purity by reversed-phase HPLC with the method conditions, and document water and counter-ion content, which together determine how much of the labeled mass is peptide. Reading a peptide certificate of analysis sets out each determination, and the stocked presentations are listed under BPC-157 research vials.

Storage and Handling of Sealed Material

BPC-157 is supplied as a lyophilized powder in a sealed vial. Store the sealed vial frozen at -20 degrees Celsius or colder, shield it from light, and avoid repeated freeze-thaw cycling of the container. Allow a cold vial to reach room temperature before opening so that atmospheric moisture does not condense onto the powder. Stability duration for a given lot is documented on its certificate of analysis. The formats the compound is supplied in are compared in BPC-157 research formats.

Reconstitution means returning a lyophilized compound to solution. The solvent system and handling for a given experiment are defined by the published methodology of the study being followed and by the receiving laboratory’s validated procedures. For the wider repair and regeneration cluster, see the healing peptides research overview and the peptide reference library.

Frequently Asked Questions

Where does BPC-157 come from?

BPC-157 is a synthetic peptide whose 15-residue sequence corresponds to a partial sequence of BPC, a protein described as isolated from human gastric juice. The reference compound is manufactured by chemical synthesis rather than extracted from a biological source, so its identity and purity are established analytically on the synthesized lot.

What does BPC stand for?

BPC stands for body protection compound, the name given by the originating research group to the gastric juice protein from which the BPC-157 sequence is taken. The suffix identifies the specific 15-residue fragment.

Why is BPC-157 called a stable gastric pentadecapeptide?

Pentadecapeptide means 15 amino acid residues. The stable gastric descriptor refers to stability in gastric juice reported in the original characterization work, and the phrase is used consistently across the published literature as the compound’s standard description.

What signaling pathways are described for BPC-157?

The published literature describes VEGFR2 signaling in association with pro-angiogenic effects, the Src-Caveolin-1-eNOS pathway in vascular preparations, and broader interaction with nitric oxide signaling. Each is reported in specific animal or cell models, and no high-affinity receptor for the peptide has been established.

Has a BPC-157 receptor been identified?

No high-affinity receptor for BPC-157 has been established in the published literature. Mechanistic work describes pathway-level effects, chiefly in angiogenic and nitric oxide signaling, rather than binding at a defined receptor.

Who conducted most of the BPC-157 research?

Most published BPC-157 work originates from a research program led by Predrag Sikiric and colleagues, beginning with characterization of the parent compound in the early 1990s. Independent replication outside that program is more limited than the total publication count suggests.

References

1. Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6). PMID 41898733.
2. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel). 2025;18(10). PMID 41155565.
3. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979.
4. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). PMID 40005999.
5. Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel). 2024;17(8). PMID 39204186.
6. Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID 34267654.
7. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID 33051481.
8. Vukojević J, Vrdoljak B, Malekinušić D, Siroglavić M, Milavić M, Kolenc D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. PMID 32558293.
9. Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID 29998800.
10. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966.
11. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PMID 21030672.
12. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, et al. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Acta Physiol Hung. 1992;80(1-4):89-98. PMID 1345210.

Educational notice. This article is for educational and informational purposes only and is intended for licensed researchers and laboratory professionals. All scientific claims are referenced to primary peer-reviewed literature.

Research-only disclaimer. BPC-157 is supplied as a research-grade reference compound for laboratory research use only. It is not for human or veterinary use. This page describes published animal-model and in vitro literature and does not describe use in people.